D

Dyne Therapeutics Tech Stack

Clinical-stage biotech developing neuromuscular disease therapies

Biotechnology Research Waltham, Massachusetts 51–200 employees Founded 2018 Public Company

Dyne Therapeutics is a public biotech company advancing therapies for rare neuromuscular diseases—DMD and DM1 in clinical stage, FSHD and Pompe in preclinical. The tech stack skews heavily toward regulated data and commercial infrastructure (Veeva Vault, WinNonlin, Salesforce, Snowflake, SAS, R), with zero adopting or replacing activity—typical of a pre-launch biotech focused on operational hardening. Active hiring mirrors imminent commercialization: 62 open roles weighted toward director-level leadership (32), sales (10), and healthcare operations (14), suggesting a shift from pure R&D into launch execution and payer access.

Tech Stack 17 technologies

Core StackTableau Power BI Snowflake Greenhouse Salesforce SAS AWS Microsoft Office Boomi Komodo ADP Workforce Now Veeva Vault PromoMats Veeva WinNonlin Veeva Vault CRM R Electronic Data Capture

What Dyne Therapeutics Is Building

◆Challenges

Coverage and reimbursement optimization
Payers access barriers
Compliance with fda regulations
Improving medication access
Ensuring compliance and data integrity
Rare disease launch readiness optimization
Building scalable medical information processes
Operational infrastructure
Securing reimbursement across global markets
Commercial launch readiness

▲Active Projects

Commercial launch readiness
Medical inquiry intake portal implementation
Launch readiness for dmd and dm1 assets
Global pricing and market access strategy
Kol engagement strategy
Us launch of dmd asset
Payer facing field tools development
Value-based model development
Developing contract templates and policies
Operating rhythm for commercial organization

Hiring Activity

Steady60 roles · 20 in 30d

Department

Healthcare

14

Sales

10

Ops

9

Data

5

Legal

5

Research

5

Marketing

4

HR

3

Seniority

Director

32

Senior

21

VP

5

Manager

2

Principal

2

Notable leadership hires: Scientific Education Lead, Data Analytics Director, Payer Strategy Director, Business Digital Platforms Lead, Compliance Director

Company intelligence

Find more companies like Dyne Therapeutics by tech stack, pain points and active projects

Get started free

About Dyne Therapeutics

Dyne Therapeutics develops therapeutics targeting muscle and the central nervous system to address genetically driven neuromuscular diseases. The company is a publicly traded clinical-stage biotech headquartered in Waltham, Massachusetts, with programs spanning Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1), facioscapulohumeral muscular dystrophy (FSHD), and Pompe disease. Current project focus is almost entirely on commercial launch readiness—including US DMD asset launch, global pricing and market access strategy, payer-facing tools, and KOL engagement—alongside buildout of medical information intake and compliance infrastructure. Key operational challenges center on coverage and reimbursement barriers, payer access, FDA compliance, and scaling medical processes for a rare disease launch.

HeadquartersWaltham, Massachusetts

Company Size51–200 employees

Founded2018

Hiring MarketsUnited States

Frequently Asked Questions

What tech stack does Dyne Therapeutics use?

Dyne uses Veeva Vault (PromoMats, CRM), WinNonlin, SAS, R, Snowflake, Salesforce, AWS, Tableau, Power BI, and ADP Workforce Now for regulatory, clinical data, analytics, and commercial operations.

What is Dyne Therapeutics working on?

Dyne is focused on commercial launch readiness for DMD and DM1 assets, including US launch execution, global pricing strategy, payer-facing tools, value-based model development, and KOL engagement.